سعر يوتاكسير 20 مجم فيال 2022

Docetaxel 20 mg for intravenous infusion, single vial.

• Breast cancer: locally advanced or metastatic after chemotherapy failure; adjuvant treatment of operable node-positive breast cancer with doxorubicin and cyclophosphamide.DailyMed (U.S. NLM)
• Non-small cell lung cancer: locally advanced or metastatic after platinum therapy failure, or with cisplatin for unresectable disease without prior chemotherapy.DailyMed (U.S. NLM)
• Metastatic castration-resistant prostate cancer with prednisone; advanced gastric adenocarcinoma and locally advanced squamous cell carcinoma of the head and neck with cisplatin and fluorouracil.DailyMed (U.S. NLM)

• Most common adverse reactions: infections, neutropenia, anemia, febrile neutropenia, hypersensitivity, thrombocytopenia, neuropathy, dysgeusia, dyspnea, constipation, anorexia, nail disorders, fluid retention, asthenia, pain, nausea, diarrhea, vomiting, mucositis, alopecia, skin reactions and myalgia.International label, equivalent formulation · DailyMed (U.S. NLM)

• Neutrophil counts below 1500 cells/mm3; history of severe hypersensitivity to docetaxel or to other drugs formulated with polysorbate 80.International label, equivalent formulation · DailyMed (U.S. NLM)

• Boxed warning: treatment-related mortality increases with abnormal liver function, higher doses and NSCLC after platinum therapy at 100 mg/m2; avoid with bilirubin above ULN or AST/ALT above 1.5 x ULN with alkaline phosphatase above 2.5 x ULN; do not give if neutrophils below 1500 cells/mm3; severe hypersensitivity reactions (contraindicated with polysorbate 80 hypersensitivity); severe fluid retention despite dexamethasone.International label, equivalent formulation · DailyMed (U.S. NLM)
• Other warnings: enterocolitis and neutropenic colitis, cystoid macular edema, second primary malignancies (e.g. AML, MDS), severe cutaneous adverse reactions, neurologic reactions, eye disorders, asthenia, alcohol content of some formulations, tumor lysis syndrome, embryo-fetal toxicity.International label, equivalent formulation · DailyMed (U.S. NLM)

• Strong CYP3A4 inhibitors (e.g. ketoconazole, itraconazole, clarithromycin, ritonavir)Docetaxel is a CYP3A4 substrate; strong inhibitors increase exposure; avoid, or consider a 50% docetaxel dose reduction with close monitoring if co-administration is unavoidable.DailyMed (U.S. NLM)

• Can cause fetal harm; advise females of reproductive potential to use effective contraception during treatment and for 2 months after the last dose, and males with female partners for 4 months after the last dose.International label, equivalent formulation · DailyMed (U.S. NLM)
• Advise women not to breastfeed during treatment and for 1 week after the last dose.International label, equivalent formulation · DailyMed (U.S. NLM)

• Docetaxel: Binds free tubulin, promotes assembly of stable microtubules and inhibits their disassembly, disrupting the microtubular network needed for mitosis (US docetaxel label).